Please assess the completion status of the following clinical trial:

Trial Title: Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has signed and dated a written informed consent~* Male or female adults (≥18 years) diagnosed with either primary ITP according to the American Society for Hematology or British Committee for Standards in Haematology (ASH/BCSH) guidelines \[Blood, 1996; British Journal of Haematology, 2003\] for at least three months prior to study entry or with ITP secondary to Evans syndrome, systemic lupus erythematosus (SLE), or Common Variable Immunodeficiency (including hypogammaglobulinemia).~* Subjects must have responded with a platelet count \> 30,000/µL to a previous ITP therapy including thrombopoietic agents.~* Platelet count \< 30,000/µL~* Female subjects of childbearing potential are practicing an acceptable method of contraception or are completely abstinent from intercourse.~Exclusion Criteria:~* Active infection~* Previously treated with thrombopoietic agents IF either no response at a therapeutic dose (peak platelet count \< 50k) OR treatment with the agent within the past 4 weeks~* Currently treated with concomitant ITP medication that has not been stable in dose for at least 2 weeks - only prednisone, azathioprin, and danazol are allowed.~* Female subjects who are nursing or pregnant~* Thrombosis of any kind within past 6 months or on blood thinners because of thrombosis.~* Intravenous Immunoglobulin (IVIG), IV anti-D, bolus corticosteroids or vinca alkaloids within the past week~* Other cytotoxic or immunosuppressive ITP therapy within the past 8 weeks or rituximab within the past 12 weeks~* Active non-dermatologic malignancy defined as presence of known tumor ie. visible by radiography or evident on blood or bone marrow testing OR receiving chemotherapy within past 2 months~* Hemoglobin \< 10 gm/dl or white blood cell count \< 2,500/ul~* Liver function tests (ALT, Aspartate Aminotransferase (AST), or total bilirubin) \> three times upper limit of normal (ULN)~* Creatinine \> two times upper limit of normal (ULN)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- eltrombopag (Type: EXPERIMENTAL): 10 ITP patients were treated with daily oral eltrombopag 75mg for 2 weeks and complete testing was done at weekly intervals 3 times they then were allowed to receive long-term eltrombopag
- romiplostim (Type: EXPERIMENTAL): 3 of the patients who received eltrombopag were also treated with romiplostim 10 micrograms/kg weekly for 2 weeks with the same complete testing done at weekly intervals three times after a washout period \> 1 month they then resumed long-term eltrombopag
- healthy controls (Type: SHAM_COMPARATOR): no intervention single blood draw with complete studies

Based on this trial design, predict the completion outcome and termination type (if applicable).